BioCentury
ARTICLE | Company News

FDA to review Titan's buprenorphine

January 3, 2013 2:18 AM UTC

FDA accepted and granted Priority Review to an NDA for Probuphine buprenorphine from Titan Pharmaceuticals Inc. (OTCBB:TTNP) to treat opioid dependence. The PDUFA date is April 30. Titan is eligible f...